Want to see VOR full AI Analyst Report?
Vor Biopharma (VOR) Stock Statistics & Valuation Metrics
Total Valuation
Vor Biopharma has a market cap or net worth of $1.16B. The enterprise value is $659.75M.
- Market Cap
- $1.16B
- Enterprise Value
- $659.75M
Share Statistics
Vor Biopharma has 59,162,292 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,162,292
- Owned by Insiders
- 9.20%
- Owned by Institutions
- 0.15%
Financial Efficiency
Vor Biopharma’s return on equity (ROE) is 4.24 and return on invested capital (ROIC) is -84.61%.
- Return on Equity (ROE)
- 4.24
- Return on Assets (ROA)
- -1.50
- Return on Invested Capital (ROIC)
- -84.61%
- Return on Capital Employed (ROCE)
- -0.85
- Revenue Per Employee
- 0
- Profits Per Employee
- -9.16M
- Employee Count
- 76
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Vor Biopharma is 0.07. Vor Biopharma’s PEG ratio is 0.00.
- PE Ratio
- 0.07
- PS Ratio
- 0.00
- PB Ratio
- -8.56
- Price to FCF
- -8.89
- Price to Operating Cash Flow
- -9.83
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Vor Biopharma had revenue of 0 and earned -695.98M in profits. Earnings per share was -70.50.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -371.64M
- Pretax Income
- -695.98M
- Net Income
- -695.98M
- EBITDA
- -693.09M
- Earnings Per Share (EPS)
- -70.50
Cash Flow
In the last 12 months, operating cash flow was -119.47M and capital expenditures -507,000, giving a free cash flow of -119.97M billion.
- Operating Cash Flow
- -119.47M
- Free Cash Flow
- -119.97M
- Free Cash Flow per Share
- -2.01
Dividends & Yields
Vor Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.25%
- Earnings Yield
- 115.28%
Stock Price Statistics
- Beta
- 5.05
- 52-Week Price Change
- -21.28%
- 50-Day Moving Average
- 20.86
- 200-Day Moving Average
- 17.38
- Relative Strength Index (RSI)
- 50.60
- Average Volume (3m)
- 950.46K
Important Dates
Vor Biopharma upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Vor Biopharma as a current ratio of 18.20, with Debt / Equity ratio of -1.83%
- Current Ratio
- 18.20
- Quick Ratio
- 18.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Vor Biopharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vor Biopharma EV to EBITDA ratio is 0.72, with an EV/FCF ratio of -8.25.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.72
- EV to Free Cash Flow
- -8.25
- EV to Operating Cash Flow
- -8.29
Balance Sheet
Vor Biopharma has $481.55M in cash and marketable securities with $2.81M in debt, giving a net cash position of $478.74M billion.
- Cash & Marketable Securities
- $481.55M
- Total Debt
- $2.81M
- Net Cash
- $478.74M
- Net Cash Per Share
- $8.09
- Tangible Book Value Per Share
- -$2.30
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Vor Biopharma is $37.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $37.67
- Price Target Upside
- 91.40% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 1
- AI Score
- 50